Eli Lilly continues to dominate the obesity market with Zepbound and Orforglipron, leading JPMorgan to see it as a top pick ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

Since the FDA said shortages of Wegovy and Zepbound are over, compounding pharmacies are supposed to stop making copies of the drugs. But some of those business are trying to find ways to continue.

Hims & Hers Health is betting that the cash-pay market for weight-loss drugs will drive up customer demand although some ...

Doctors favor treatment with continuous positive airway pressure (CPAP) machines, researchers are slated to report this week ...

People using GLP-1 drugs like Ozempic are reporting "Ozempic teeth," an unusual side effect impacting dental health. "Ozempic ...

With IRS tax refunds set to arrive, averaging around $3,000, many Americans are weighing the best ways to use the extra cash.

Poison-control centers are seeing a steady increase in calls related to weight-loss drugs, and the FDA shared a report ...

Over the past few years, demand for blockbuster medications like Ozempic, Wegovy and Zepbound skyrocketed ... Tina decided to buy a six-month supply, which cost around $1,450.

Zepbound (tirzepatide) and Wegovy (semaglutide) are prescription drugs used for weight loss and weight management. Both drugs come as a liquid solution for injection under the skin. Zepbound and ...

Novo Nordisk is rapidly ceding market share to Eli Lilly. And the paradigm shift is showing up in Novo Nordisk stock.